TRKB-based signature identifies high-risk squamous cell carcinoma cases and TRKB blockade reprograms tumor and stromal cells toward suppressive phenotypes
Our findings provide a basis for improved high-risk patient stratification by highlighting a TrkB-based signature and generating prototype predictive models. Furthermore, they offer promising therapeutic avenues for developing combined targeted interventions to overcome resistance in high-risk patients.
Authors
- Rosanna Monetta (ORCID: https://orcid.org/0000-0001-7984-5804)
- Alessio Capone
- Massimo Teson (ORCID: https://orcid.org/0000-0002-7179-1255)
- Carola Valente (ORCID: https://orcid.org/0000-0001-9234-2267)
- Elena Dellambra (ORCID: https://orcid.org/0000-0002-4329-3312)
- Luca Fania (ORCID: https://orcid.org/0000-0003-4194-932X)
- Mara Mancini (ORCID: https://orcid.org/0000-0001-5173-4854)
- Giovanni Di Lella (ORCID: https://orcid.org/0000-0002-5945-7860)
- Vito Enzo Gomes
- Simona Mastroeni (ORCID: https://orcid.org/0000-0002-8396-5347)
- Giovanni Luca Scaglione (ORCID: https://orcid.org/0000-0001-5622-7843)
- Valeria Bartolocci (ORCID: https://orcid.org/0009-0004-4005-2910)
- Candi Eleonora
- Denise Campagna
- Silvia Arcano
- Damiano Abeni
- Francesca Ricci
- Erika Di Meo
Institutions
- University of Rome Tor Vergata (IT)
- Istituto Superiore di Sanità (IT)
- National Centre for Disease Prevention and Control (IT)
- Istituto Dermopatico dell'Immacolata (IT)
Publication Details
- Journal
- Journal of Biomedical Science
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1186/s12929-026-01227-0
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00